LPL and metabolic syndrome: Clinically, RC monitoring could identify candidates for intensified therapy, such as fibrates or omega-3 fatty acids, which reduce RC by 25–40% through enhanced lipoprotein lipase activity—a strategy supported by trial data showing RC-lowering interventions reduce recurrent ischemia in metabolic syndrome populations [22, 24].